A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.
Wass M, Göllner S, Besenbeck B, Schlenk RF, Mundmann P, Göthert JR, Noppeney R, Schliemann C, Mikesch JH, Lenz G, Dugas M, Wermke M, Röllig C, Bornhäuser M, Serve H, Platzbecker U, Foerster KI, Burhenne J, Haefeli WE, Müller LP, Binder M, Pabst C, Müller-Tidow C; Study Alliance Leukemia (SAL).
Wass M, et al. Among authors: platzbecker u.
Leukemia. 2021 Mar;35(3):701-711. doi: 10.1038/s41375-020-0892-z. Epub 2020 Jun 19.
Leukemia. 2021.
PMID: 32561840
Free PMC article.
Clinical Trial.